| scholarly article | Q13442814 |
| P50 | author | Jürgen Rockstroh | Q47006499 |
| Hans-Jürgen Stellbrink | Q47158312 | ||
| Jan van Lunzen | Q47159113 | ||
| P2093 | author name string | Stefan Reuter | |
| Hans-Jürgen Stellbrink | |||
| Matthias Stoll | |||
| Christian Kollan | |||
| Osamah Hamouda | |||
| Frank Bergmann | |||
| Andreas Plettenberg | |||
| Johannes Bogner | |||
| Carlos Fritzsche | |||
| Gerd Faetkenheuer | |||
| Kirsten Hoeper | |||
| Heinz-August Horst | |||
| Barbara Bartmeyer | |||
| P2860 | cites work | Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. | Q51931076 |
| Pricing behaviour of pharmacies after market deregulation for OTC drugs: the case of Germany. | Q52925718 | ||
| Side effects of generic competition? | Q81407388 | ||
| German health care system in transition. The difficult way to balance cost containment and solidarity | Q81773003 | ||
| Pharmaceutical policies: effects of restrictions on reimbursement | Q24236533 | ||
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 | ||
| Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach | Q31168464 | ||
| Impact of pharmacy benefit design on prescription drug utilization: a fixed effects analysis of plan sponsor data | Q33404862 | ||
| The direct costs of HIV/AIDS care | Q34497622 | ||
| The survival benefits of AIDS treatment in the United States | Q34533291 | ||
| Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases | Q37246018 | ||
| Simplification strategies to reduce antiretroviral drug exposure: progress and prospects | Q37277829 | ||
| Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review. | Q37649655 | ||
| Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis | Q37744727 | ||
| A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine | Q40042881 | ||
| In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. | Q40270653 | ||
| Cohort profile: the German ClinSurv HIV project - a multicentre open clinical cohort study supplementing national HIV surveillance | Q42678929 | ||
| Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study | Q42678935 | ||
| The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study | Q43138403 | ||
| Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy | Q43145005 | ||
| Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. | Q44043547 | ||
| Generic script share and the price of brand-name drugs: the role of consumer choice | Q46117047 | ||
| Comparing the acid-suppressive effects of three brands of generic lansoprazole with the original: pharmacokinetic bioequivalence tests do not necessarily guarantee pharmacodynamic equivalence | Q46192189 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anti-retroviral agent | Q50430310 |
| P304 | page(s) | e23946 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort | |
| P478 | volume | 6 |
| Q40743211 | A Regional Drug and Therapeutics Committee-led Intervention to Reduce the Hospital Costs of Expensive HIV Drugs. |
| Q37077894 | Analysis of contemporary HIV/AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines. |
| Q31034000 | Antiretroviral therapy for HIV/AIDS in claims data from statutory health insurance funds in Germany |
| Q42229844 | Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start |
| Q36226270 | Cost of human immunodeficiency virus infection in Italy, 2007-2009: effective and expensive, are the new drugs worthwhile? |
| Q30925594 | From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany |
| Q38717415 | Generic substitution of antiretrovirals: patients' and health care providers' opinions |
| Q36234850 | HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy |
| Q34474070 | HIV-prevalence in tuberculosis patients in Germany, 2002-2009: an estimation based on HIV and tuberculosis surveillance data |
| Q40513800 | Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen. |
| Q26865049 | The Effect on Treatment Adherence of Administering Drugs as Fixed-Dose Combinations versus as Separate Pills: Systematic Review and Meta-Analysis |
| Q37547161 | The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment - results from an observational study in Germany |
Search more.